BLI Logo Aug 2021.jpg
Berkeley Lights to Present on Cell Line Development of Complex Molecules and Accelerating Antibody Discovery Against Difficult Targets at 13th Annual PEGS Europe
01 nov. 2021 16h05 HE | Berkeley Lights, Inc
EMERYVILLE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in digital cell biology, today announced its participation at the 13th Annual PEGS Europe: Protein...
Aldevron Now Utilizing Berkeley Lights' Beacon® Platform
11 juin 2019 07h02 HE | Aldevron
Fargo, N.D., June 11, 2019 (GLOBE NEWSWIRE) -- Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic...
Aldevron Now Utilizing Berkeley Lights' Beacon® Platform
11 juin 2019 00h02 HE | Aldevron
Fargo, N.D., June 11, 2019 (GLOBE NEWSWIRE) -- Aldevron, a global leader in antibody discovery to the biotech industry, announced today the acquisition and installation of the Beacon Optofluidic...
Vaccinex logo
Vaccinex, Inc. Announces Research Collaboration Employing ActivMAb® Platform Technology and Antibody License Option Agreement with Surface Oncology
08 janv. 2018 13h10 HE | Vaccinex, Inc.
ROCHESTER, N.Y., Jan. 08, 2018 (GLOBE NEWSWIRE) -- Vaccinex, Inc., a privately-held clinical-stage biotechnology company engaged in the development of therapeutic monoclonal antibodies to treat...
AbCellera Announces
AbCellera Announces Expanded Research Collaboration with Teva
13 juin 2017 09h00 HE | AbCellera
VANCOUVER, British Columbia, June 13, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Teva Pharmaceutical Industries, Ltd....
AbCellera Announces
AbCellera Announces an Antibody Discovery Program in Influenza Vaccine Research
06 juin 2017 09h00 HE | AbCellera
VANCOUVER, British Columbia, June 06, 2017 (GLOBE NEWSWIRE) -- AbCellera has entered into a collaborative research effort with Sanofi Pasteur, a global leader in the development and sale of vaccines...
AbCellera Announces
AbCellera Announces Multi-Target Research Collaboration with Pfizer
05 janv. 2017 09h00 HE | AbCellera
VANCOUVER, British Columbia, Jan. 05, 2017 (GLOBE NEWSWIRE) -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Pfizer Inc. (NYSE:PFE). AbCellera...
AbCellera Completes
AbCellera Completes Antibody Discovery Project With Kodiak Sciences to Identify Lead Therapeutic Candidates
24 août 2016 09h00 HE | AbCellera
VANCOUVER, British Columbia, Aug. 24, 2016 (GLOBE NEWSWIRE) -- AbCellera Biologics Inc., a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune...
AbCellera and MassBi
AbCellera and MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria
20 juil. 2016 09h00 HE | AbCellera
VANCOUVER, British Columbia, July 20, 2016 (GLOBE NEWSWIRE) -- AbCellera Biologics Inc., a biotechnology company specializing in the rapid discovery of monoclonal antibodies from natural immune...
Teva and AbCellera E
Teva and AbCellera Enter Into Agreement to Discover Rare Monoclonal Antibodies
02 févr. 2016 08h00 HE | AbCellera
JERUSALEM and VANCOUVER, British Columbia, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) (TASE:TEVA) and AbCellera have entered into a collaborative research...